Abstract | PURPOSE: To study the human pharmacokinetics and in vitro cytotoxicity of Apomine, an p.o. administered, nonmyelosuppressive agent that selectively inhibits cell proliferation and induces tumor cell apoptosis through the farnesoid X receptor. EXPERIMENTAL DESIGN: RESULTS: Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg. h/ml (308 microM. h), and a mean t(1/2 (24--192 h)) of 156.2 +/- 42.9 h. In vitro assay results showed that 63 and 91% of the ovarian cancers were sensitive (i.e., >70% inhibition of tumor cell growth) to Apomine at concentrations of 10 and 20 microM. The sensitivity rates were 91% for carboplatin (270 microM), 88% for cisplatin (33 microM), 41% for paclitaxel (5.9 microM), and 85% for topotecan (2.2 microM). CONCLUSIONS: These in vitro assay results, taken together with our preliminary plasma pharmacokinetic data, suggest that Apomine should be clinically active at the 125 mg/m(2) dose level.
|
Authors | D S Alberts, A V Hallum 3rd, M Stratton-Custis, D J Garcia, M Gleason-Guzman, S E Salmon, P Santabarbara, E J Niesor, S Floret, C L Bentzen |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 7
Issue 5
Pg. 1246-50
(May 2001)
ISSN: 1078-0432 [Print] United States |
PMID | 11350890
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Diphosphonates
- apomine
|
Topics |
- Administration, Oral
- Antineoplastic Agents
(pharmacokinetics, therapeutic use)
- Cell Division
(drug effects)
- Diphosphonates
(pharmacokinetics, therapeutic use)
- Drug Screening Assays, Antitumor
- Female
- Humans
- Male
- Neoplasms
(drug therapy, metabolism)
- Tumor Cells, Cultured
|